Literature DB >> 30043173

Sarcopenia definition in patients with NAFLD.

Tao-Chun Peng1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30043173     DOI： 10.1007/s00535-018-1496-5

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  4 in total

1.  Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease.

Authors:  Naoki Mizuno; Yuya Seko; Seita Kataoka; Keiichiroh Okuda; Mitsuhiro Furuta; Masashi Takemura; Hiroyoshi Taketani; Tasuku Hara; Atsushi Umemura; Taichiro Nishikawa; Kanji Yamaguchi; Michihisa Moriguchi; Yoshito Itoh
Journal:  J Gastroenterol       Date:  2018-06-14       Impact factor: 7.527

2.  Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): The importance of sarcopenia definition.

Authors:  Tao-Chun Peng; Li-Wei Wu; Wei-Liang Chen; Fang-Yih Liaw; Yaw-Wen Chang; Tung-Wei Kao
Journal:  Clin Nutr       Date:  2017-12-08       Impact factor: 7.324

3.  Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.

Authors:  Bo Kyung Koo; Donghee Kim; Sae Kyung Joo; Jung Ho Kim; Mee Soo Chang; Byeong Gwan Kim; Kook Lae Lee; Won Kim
Journal:  J Hepatol       Date:  2016-09-04       Impact factor: 25.083

4.  Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).

Authors:  Yong-ho Lee; Seung Up Kim; Kijun Song; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Byung-Wan Lee; Eun Seok Kang; Bong-Soo Cha; Kwang-Hyub Han
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.